Black Rock Inc. Provention Bio, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$6.7 - $24.21 $581,178 - $2.1 Million	86,743 Added 1.55%	5,666,347 $137 Million
Q4 2022 Feb 13, 2023	BUY	$4.52 - $10.57 $2.48 Million - $5.81 Million	549,256 Added 10.92%	5,579,604 $59 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $1.46 Million - $2.38 Million	424,311 Added 9.21%	5,030,348 $22.6 Million
Q2 2022 Aug 12, 2022	BUY	$3.65 - $7.3 $782,147 - $1.56 Million	214,287 Added 4.88%	4,606,037 $18.4 Million
Q1 2022 May 12, 2022	SELL	$3.4 - $7.88 $313,395 - $726,339	-92,175 Reduced 2.06%	4,391,750 $32.1 Million
Q4 2021 Feb 10, 2022	SELL	$5.59 - $7.39 $38,017 - $50,259	-6,801 Reduced 0.15%	4,483,925 $25.2 Million
Q3 2021 Nov 09, 2021	SELL	$5.66 - $8.33 $319,342 - $469,986	-56,421 Reduced 1.24%	4,490,726 $28.7 Million
Q2 2021 Aug 11, 2021	BUY	$6.71 - $11.04 $30.5 Million - $50.2 Million	4,547,147 New	4,547,147 $38.3 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.